TY - JOUR T1 - Schizophrenia polygenic risk score and cannabis use modify psychosis expression in first episode psychosis patients and population controls JF - medRxiv DO - 10.1101/19013284 SP - 19013284 AU - Diego Quattrone AU - Ulrich Reininghaus AU - Alex L. Richards AU - Giada Tripoli AU - Laura Ferraro AU - Paolo Marino AU - Victoria Rodriguez AU - EU-GEI group AU - Charlotte Gayer-Anderson AU - Hannah E. Jongsma AU - Peter B. Jones AU - Caterina La Cascia AU - Daniele La Barbera AU - Ilaria Tarricone AU - Elena Bonora AU - Sarah Tosato AU - Antonio Lasalvia AU - Andrei Szöke AU - Celso Arango AU - Miquel Bernardo AU - Julio Bobes AU - Cristina Marta Del Ben AU - Paulo Rossi Menezes AU - Pierre-Michel Llorca AU - Jose Luis Santos AU - Julio Sanjuán AU - Andrea Tortelli AU - Eva Velthorst AU - Lieuwe de Haan AU - Bart P.F. Rutten AU - Michael T. Lynskey AU - Tom P. Freeman AU - James B. Kirkbride AU - Pak C. Sham AU - Michael C. O’Donovan AU - Alastair Cardno AU - Evangelos Vassos AU - Jim van Os AU - Craig Morgan AU - Robin M. Murray AU - Cathryn M. Lewis AU - Marta Di Forti Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/11/29/19013284.abstract N2 - Background Diagnostic categories within the psychosis spectrum are widely used in clinical practice, however psychosis may occur on a continuum. Therefore, we explored whether the continuous distribution of psychotic symptoms across categories is a function of genetic as well as environmental risk factors, such as polygenic risk scores (PRSs) and cannabis use.Methods As part of the EU-GEI study, we genotyped first episode psychosis patients (FEP) and population controls, for whom transdiagnostic dimensions of psychotic symptoms or experiences were generated using item response bi-factor modelling. Linear regression was used, separately in patients and controls, to test the associations between these dimensions and schizophrenia (SZ) PRSs, as well as the combined effect of SZ-PRS and cannabis use on the positive symptom/experience dimensions.Results SZ-PRS was associated with negative (B=0.18; 95%CI 0.03 to 0.34) and positive (B=0.19; 95%CI 0.03 to 0.36) symptom dimensions in 617 FEP, and with all the psychotic experience dimensions in 979 controls. The putative effect of SZ-PRS on either symptom or experience dimensions was of a small magnitude. Cannabis use was additionally associated with the positive dimensions both in FEP (B=0.31; 95%CI 0.11 to 0.52) and in controls (B=0.26; 95%CI 0.06 to 0.46), independently from SZ-PRS.Conclusions We report two validators to the latent dimensional structure of psychosis. SZ risk variants and cannabis use independently map onto specific dimensions, contributing to variation across the psychosis continuum. Findings support the hypothesis that psychotic experiences have similar biological substrates as clinical disorders.Competing Interest StatementFinancial Disclosures M Di Forti reports personal fees from Janssen, outside the submitted work. R M Murray reports personal fees from Janssen, Lundbeck, Sunovion, and Otsuka, outside of the submitted work. M Bernardo reports grants and personal fees from Adamed, Janssen-Cilag, Otsuka, and Abbiotics; personal fees from Angelini and Casen Recordati; and grants from Lundbeck and Takeda, outside of the submitted work. PB Jones reports personal fees from being a member of the scientific advisory boards for Janssen and Ricordati, outside of the submitted work. C Arango reports personal fees from Acadia, Ambrosseti, Gedeon Richter, Janssen Cilag, Lundbeck, Merck, Otsuka,Roche, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion, and Takeda; and grants from CIBERSAM, Familia Alonso, Fundaci.n Alicia Koplowitz, the European Commission, the Spanish Ministry of Science and Universities, and the Comunidad de Madrid, during the conduct of the study. J Bobes has received research grants and served as consultant, advisor or speaker for AB-Biotics, Acadia Pharmaceuticals, Ambrosseti-Angelini, Casen Recordati, D&A Pharma, Exeltis, Gilead, Indivior, Janssen-Cilag, Lundbeck, Mundipharma, Otsuka, Pfizer, Roche, Sage Therapeutics, Servier, Schwabe Farma Ibérica, Shire, Takeda, research funding from the Spanish Ministry of Economy and Competiveness -Centro de Investigación Biomedica en Red area de Salud Mental (CIBERSAM) and Instituto de Salud Carlos III-, Spanish Ministry of Health, Social Services and Equality - Plan Nacional sobre Drogas outside of the submitted work. Dr Diego Quattrone reported no biomedical financial interests or potential conflicts of interest. Dr Alexander L Richards reported no biomedical financial interests or potential conflicts of interest. Dr Tom P Freeman reported no biomedical financial interests or potential conflicts of interest. Ms Giada Tripoli reported no biomedical financial interests or potential conflicts of interest. Dr Charlotte Gayer-Anderson reported no biomedical financial interests or potential conflicts of interest. Dr Victoria Rodriguez reported no biomedical financial interests or potential conflicts of interest. Dr Hannah E Jongsma reported no biomedical financial interests or potential conflicts of interest. Dr Laura Ferraro reported no biomedical financial interests or potential conflicts of interest. Dr Caterina La Cascia reported no biomedical financial interests or potential conflicts of interest. Dr Sarah Tosato reported no biomedical financial interests or potential conflicts of interest. Dr Ilaria Tarricone reported no biomedical financial interests or potential conflicts of interest. Dr Elena Bonora reported no biomedical financial interests or potential conflicts of interest. Dr Marco Seri reported no biomedical financial interests or potential conflicts of interest. Dr Giuseppe D’Andrea reported no biomedical financial interests or potential conflicts of interest. Dr Andrei Szöke reported no biomedical financial interests or potential conflicts of interest. Julio Sanjuán, Jose Luis Santos, Dr Manuel Arrojo reported no biomedical financial interests or potential conflicts of interest. Dr Eva Velthorst reported no biomedical financial interests or potential conflicts of interest. Dr Cristina Marta Del-Ben reported no biomedical financial interests or potential conflicts of interest. Dr Jean-Paul Selten reported no biomedical financial interests or potential conflicts of interest. Dr James B Kirkbride reported no biomedical financial interests or potential conflicts of interest. Dr Bart PF Rutten reported no biomedical financial interests or potential conflicts of interest. Dr Lieuwe de Haan reported no biomedical financial interests or potential conflicts of interest. Dr Jim van Os reported no biomedical financial interests or potential conflicts of interest. Dr Michael Lynskey reported no biomedical financial interests or potential conflicts of interest. Dr Craig Morgan reported no biomedical financial interests or potential conflicts of interest. Dr Evangelos Vassos reported no biomedical financial interests or potential conflicts of interest. EU-GEI WP2 Group, Dr Michael O’ Donovan is supported by a collaborative research grant from Takeda outside of the submitted work. Dr Cathryn M Lewis reported no biomedical financial interests or potential conflicts of interest. Dr Pak C Sham reported no biomedical financial interests or potential conflicts of interest.Funding StatementThe work was supported by: Clinician Scientist Medical Research Council fellowship (project reference MR/M008436/1) to MDF; the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King's College Hospital NHS Foundation Trust to DQ.; National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The EU-GEI Project is funded by the European Community’s Seventh Framework Programme under grant agreement No. HEALTH-F2-2010-241909 (Project EU-GEI). The Brazilian study was funded by the São Paulo Research Foundation under grant number 2012/0417-0. Funders were not involved in design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript, and decision to submit the manuscript for publication.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAny request has to be considered under the provision of the EU-GEI project procedures ER -